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Abstract
Background: Preclinical studies of overlapping 15mer peptides, spanning SIV, SHIV or HIV, pulsed on autologous PBMC ex
vivo have demonstrated high level, virus-specific T cell responses and viral suppression in non-human primates (NHP). Opal-
HIV-Gag(c) consists of 120 synthetic 15mer peptides spanning Clade C, consensus Gag, manufactured to current good
manufacturing practice; having been evaluated in a good laboratory practice toxicology study in Macaca mulatta. We
evaluated the safety and preliminary immunogenicity of such peptides administered intravenously after short-duration ex
vivo incubation, to HIV-positive adults on suppressive antiretroviral therapy.
Methods and Findings: A first-in-human, placebo-controlled, double-blind, dose escalation study was conducted. Twenty-
three patients with virus suppressed by antiretroviral therapy were enrolled in four groups 12 mg (n=6), 24 mg (n=6),
48 mg (n=2) or matching placebo (n=8). Treatment was administered intravenously after bedside enrichment of 120 mL
whole blood for white cells using a closed system (Sepax S-100 device), with ex vivo peptide admixture (or diluent alone)
and 37uC incubation for one hour prior to reinfusion. Patients received 4 administrations at monthly intervals followed by a
12-week observation post-treatment. Opal-HIV-Gag(c) was reasonably tolerated at doses of 12 and 24 mg. There was an
increased incidence of temporally associated pyrexia, chills, and transient/self-limiting lymphopenia in Opal-HIV-Gag(c)
recipients compared to placebo. The study was terminated early, after two patients were recruited to the 48 mg cohort; a
serious adverse event of hypotension, tachycardia secondary to diarrhoea occurred following a single product
administration. An infectious cause for the event could not be identified, leaving the possibility of immunologically
mediated product reaction.
Conclusions: A serious, potentially life-threatening event of hypotension led to early, precautionary termination of the
study. In the absence of a clearly defined mechanism or ability to predict such occurrence, further development of Opal-HIV-
Gag(c) will not be undertaken in the current form.
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HIV remains a significant global health problem, despite the
availability of a range of antiretroviral treatments and strategies.
An estimated 2.7 million people were newly infected with HIV
and approximately 1.8 million died from HIV/AIDS in 2011 [1].
The use of combination highly active antiretroviral therapy
(HAART) has significantly improved prospects for HIV infected
individuals and has lowered transmission rates. However, the
treatment regimens are complex, expensive and may be associated
with treatment-limiting side effects and the emergence of drug
resistant viral strains. These factors remain critical barriers to the
management of HIV/AIDS, particularly in economically disad-
vantaged communities. The availability of an immunotherapy,
which either delays the introduction of HAART or complements
treatment by HAART, would be an important advance in treating
HIV.
The induction of HIV-specific T-cell responses is critical to
effective control of viraemia and delaying subsequent progression
to AIDS [2–4]. Cytotoxic T-lymphocyte responses to the HIV
structural protein Gag have been consistently associated with low
viral load [5,6], with evidence that viral escape from Gag-specific
T-cell responses occurs at the expense of viral fitness [5,7–9]. This
suggests that Gag-specific cellular immune responses may be an
appropriate target antigen for an HIV therapeutic vaccine.
Overlapping peptide-pulsed autologous lymphocytes (OPAL) is
a novel immunotherapy being developed for the treatment of
HIV. The therapy involves pulsing autologous peripheral blood
mononuclear cells (PBMCs), enriched white blood cells (WBCs) or
whole blood ex vivo, with a mixture of synthetic 15mer peptides
overlapping by 11 amino acids. This approach, used in non-
human primates, induced high-frequency, broad, polyfunctional
CD4+ and CD8+ SIV-specific T cell responses [7–10] that
resulted in a sustained, 10-fold reduction in SIV viral load in
vaccinated animals [10,11].
The vaccine for clinical evaluation, Opal-HIV-Gag(c), was
manufactured to match the Gag clade C Durban consensus
sequence [6]. The clade C subtype circulates in Southern Africa,
India, and China, and is responsible for over 50% of all HIV
infections worldwide [12]. Since Gag is highly conserved across
clades, it was reasoned that Opal-HIV-Gag(c) would have broad
cross-clade reactivity [11,13–15].
This phase I study was the first step to determine whether the
immunotherapy Opal-HIV-Gag(c) might have utility as a treat-
ment for HIV when administered ex vivo to enriched WBCs. The
aim was to evaluate the safety of the study vaccine, Opal-HIV-
Gag(c) compared to placebo, at three dose concentrations. The
secondary aim was to evaluate the immunogenicity in T-cells and
to assess the impact of Opal-HIV-Gag(c) on HIV infection. The
study was terminated early for safety reasons.
Methods
The protocol for this trial and supporting CONSORT checklist
are available as supporting information; see Checklist S1 and
Protocol S1.
Ethics Statement and Regulatory Approvals
The protocol, designated Opal-HIV-1001 and titled ‘‘A phase
1, dose escalating, single centre, double blind study of the safety
and immunogenicity of Opal-HIV-Gag(c) in HIV-1 positive
subjects’’ was sponsored by Medicines Development, Melbourne,
Australia. The study was conducted in compliance with the
International Conference on Harmonisation Good Clinical
Practice, the Declaration of Helsinki, and was registered with
EudraCT 2008-005142-23 prior to enrolment of participants.
Ethical approval was granted by the The Royal Marsden Ethics
Committee of the National Research Ethics Service, UK. All study
participants voluntarily provided written informed consent before
any study procedures were undertaken.
Objectives
The primary objective was to assess the safety of Opal-HIV-
Gag(c) at three dose concentrations compared to placebo in HIV-1
individuals receiving stable HAART, while the secondary objec-
tives were to evaluate the immunogenicity and impact of Opal-
HIV-Gag(c)) treatment on HIV-1 infection.
Study Design and Participants
This was a phase I, first-in-human, double blind, placebo
controlled, randomised, dose escalation study conducted at a
single centre, Chelsea & Westminster Hospital, London, UK from
May 2010 to October 2011. Participants were recruited from the
ambulatory clinics at Chelsea & Westminster Hospital, London
UK, Royal Berkshire Hospital, Reading UK and Northampton-
shire General Hospital, Northampton, UK. After discussion and
written confirmation of informed consent, eligibility was confirmed
according to the following major criteria: aged 18–60 years,
inclusive; HIV-1 infected; receiving stable antiretroviral therapy
with at least 3 active drugs for a minimum of 2 months and with
undetectable viral load for 6 months prior to planned study
baseline; CD4+ T-cell counts .350 cells/mm
3 with a nadir .100
cells/mm
3, and a positive ex vivo or 10 day cultured IFNc ELIspot
assay to Opal-HIV-Gag(c) peptides. Exclusion criteria included:
infection with hepatitis B or C; an AIDS defining condition within
42 days of Baseline; having received any immunomodulatory
agents/vaccine within 60 days or any blood products within 6
months of Screening. The full inclusion/exclusion criteria for the
study can be found in protocol S1.
The study protocol planned to enrol a total of up to 27 patients
in three sequentially completed, ascending-dose cohorts of 9
patients each. Within each cohort, patients were randomised to
receive Opal-HIV-Gag(c) (n=6) or placebo (DMSO, n=3) and
stratified by Clade. In addition, a sentinel cohort of one Opal-
HIV-Gag(c) and one placebo patient were dosed prior to the
balance of the cohort. The randomisation code was computer
generated and prepared by an independent statistician. Partici-
pants received doses at 4 weekly intervals on Day zero and weeks
4, 8 and 12 followed by a 12 week post-treatment follow-up safety
period. Dose escalation was permitted after all participants at each
dose level completed at least 2 doses and the safety data were
reviewed by the independent Data Safety Monitoring Board.
Patients were monitored throughout the study for adverse events,
concurrent medications, physical findings, vital signs, immunolog-
ical markers, viral load, CD4+ T cell counts, and safety bloods.
Clinical trial monitoring was performed by AptivSolutions,
Hemel Hempstead, UK; biochemistry, haematology, viral load
and T-cell enumeration was conducted by The Doctor’s
Laboratory, London, UK; HLA genotyping was conducted the
University of Oklahoma Health Sciences Centre, OK, USA; data
management and statistical analysis for the study was performed
by iNC Research, Oakleigh, Australia, and; immunogenicity was
evaluated at Imperial College, London, UK and Oxford
University, Oxford, UK.
Interventions and Vaccines
Opal-HIV-Gag(c) consists of 120 peptides of 15 amino acids in
length overlapping the preceding proceeding peptide by 11 amino
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Gag protein consensus sequence and were manufactured to
current Good Manufacturing Practice as defined by United States
Part 21 Code of Federal Regulations by CS Bio, Inc. (San Mateo,
CA). All 120 peptides were mixed in equal weight quantities,
lyophilised and terminally gamma irradiated. A repeat dose Good
Laboratory Practice toxicology study was completed in non-
human primates prior to initiation of this study.
Opal-HIV-Gag(c) was reconstituted prior to administration in
dimethyl sulfoxide (DMSO) United States Pharmacopoea (WAK
Chemie GmbH, Germany). DMSO at the identical concentration
was used as the placebo.
Opal-HIV-Gag(c) and diluent were stored frozen at
220uC65uC in an entry restricted and temperature-monitored
facility at the study site and thawed immediately prior to use, with
doses prepared individually.
Opal-HIV-Gag(c) or placebo were administered by drawing
120 mL of whole blood, enriching the white blood cells into a
resultant 20 mL volume using a Sepax S-100 cell separation
device (Biosafe SA, Switzerland) adding Opal-HIV-Gag(c) and
were incubated at 37uC for one hour, prior to intravenous re-
infusion. The concentration of DMSO in the reinfusion was 4%
for both Opal-HIV-Gag(c)) or placebo.
The clinical doses were selected based on the non-human
primate efficacy and safety studies. In the repeat dose toxicology
study in non-human primates, the maximum dose was 5 doses of
18.5 mg Opal-HIV-Gag(c), which is the equivalent of 74 mg/
square metre (m
2) of Body Surface Area (BSA) (assumes 0.25 m
2
BSA for a monkey of 3 kilograms [kg]), or 6.2 mg/kg at each of
the 5 administrations and this was also determined to be the no
observable adverse effect level (NOAEL). The clinical starting dose
was 12 mg or 7.4 mg/m
2 (0.2 mg/kg, assuming 1.62 m
2 BSA for
a 60 kg human) at each of four administrations and the maximum
dose proposed in the clinical trial was 48 mg or 29.6 mg/m
2
(0.8 mg/kg). Hence, the first-in-human starting dose for the study
was approximately 10 times lower than the NOAEL in non-
human primates (based on the USA Food and Drug Administra-
tion Guidance for Industry and Reviewers Estimating the Safe
Starting Dose in Clinical Trials for Therapeutics in Adult Healthy
Volunteers [9]). Though the patients recruited to this study were
infected with HIV-1, the eligibility criteria were suitably defined
such that their health status (on stable antiretroviral therapy) could
otherwise reasonably be classified as healthy adult participants.
Immunogenicity
The induction of T-cell immunogenicity was assessed by using
ex vivo ELISpot responses using Opal-HIV-Gag(c), Tat, Rev, Nef, a
mock as a negative control and cytomegalovirus peptides to
stimulate T-cells in accordance with the laboratories’ standard
procedures.
Sample Size and Statistical Design
The methodology for reporting study data was detailed in the
Statistical Analysis Plan (SAP). Appropriate descriptive statistics
for the data were determined using SAS (version 9.2 - SAS
Institute Inc., Cary, North Carolina, USA). Adverse events were
coded according to the Medical Dictionary for Regulatory
Activities (MedDRA) (version 12.0). Concomitant medications
were coded using the latest version (Quarter 2, 2010) of the World
Health Organisation (WHO) Drug coding dictionary. All data
compiled for participants prior to the point of discontinuation has
been used for analyses with all withdrawals being included in
analysis up to the time of withdrawal regardless of duration of
treatment. No substitutions were made for missing data. All
analyses were based on available data, unless otherwise stated.
Blinded interim reviews of immunogenicity data (to W14) were
conducted after the 12 mg and 24 mg Cohorts were completed.
All statistical analyses were carried out using two sided tests at
the 5% level of significance. In cases where the parameters did not
follow a normal distribution, log transformations were used. If the
log transformed data was not normally distributed, a non-
parametric test (Kruskal-Wallis) was used to analyse the difference
in population medians.
The sample size for the study was selected based on industry
guidance and Phase I study design [13–16] and, as such, no formal
sample size calculation was performed for this study.
Results
Study Population
Twenty three patients satisfied the inclusion and exclusion
criteria and were randomised to receive 12 mg (n=6), 24 mg
(n=6), 48 mg (n=2) or placebo (n=9, with only 8 being analysed
after receiving intervention). Five participants withdrew from the
study: one patient, allocated to receive placebo, due to equipment
failure prior to treatment administration (this patient was
replaced); 1 receiving 48 mg withdrew due to a serious adverse
event (SAE) leading to early study termination; and three patients
(n=1 48 mg, n=2 placebo) were required to withdraw when the
study was terminated. In addition, one patient with elevated ALT
due to concurrent therapy withdrew from treatment but remained
on the study. Despite the small number of patients, the
demographic characteristics of the cohorts were not markedly
different (Table S1).
Impact of OPAL-HIV-Gag(c) on HIV Viral Load and
Absolute CD4 Counts
HIV-1 viral load remained well controlled, without any result,
confirmed by repeat, above 50 copies/ml for all study patients
throughout the study period (not shown), indicating an absence of
viral rebound. In all cohorts, CD4+ cell count varied around a
stable plateau, consistent with the pattern of variability seen in
normal clinical follow-up and with no temporal association with
administration of Opal-HIV-Gag(c)) or placebo (data not shown).
Safety Analyses
Opal-HIV-Gag(c) was generally well tolerated. The most
commonly occurring AEs (ranked on total number of participants
in all treatment cohorts experiencing AE) are presented in Table
S2. At the 12 mg or 24 mg cohorts, there was no evidence of an
increasing incidence or severity of adverse events with increasing
dose and there was a similar number of events in patients receiving
Opal-HIV-Gag(c) or placebo. Body temperature increases were
temporally associated with Opal-HIV-Gag(c), regardless of dose,
and there was an increased incidence of rigors, chills and transient
lymphopenia temporally associated with Opal-HIV-Gag(c) but not
placebo treatment.
The second patient randomised to receive 48 mg Opal-HIV-
Gag(c) experienced a treatment and study-terminating SAE. The
event was comprised of hypotension, tachycardia, diarrhoea, and
anuria. The patient, a 53-year-old male originally from Kenya,
was infected with HIV-1 clade B/D virus since 2006 and had
achieved virologic suppression with tenofovir, emtricitabine and
efavirenz since shortly after diagnosis. Pre-treatment, he reported
good health with no clinically relevant abnormalities detected on
full physical examination or in baseline laboratory values. Within 2
hours of completion of the first infusion, he began to experience
cramping, abdominal discomfort and subsequently passed large
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hour, with simultaneous vomiting on two occasions. There was no
blood present in either stool or vomit, and examination revealed a
quiescent abdomen following evacuation with no evidence of rash
or angioedema. Though afebrile during this period, the fluid losses
resulted in a hypovolaemic state with a drop in systolic blood
pressure, tachycardia and tachypnoea. No specific therapy was
administered to manage any presumed cause of this event, with
only intravenous fluid replacement and low molecular weight
heparin to prevent venous thrombosis. The patient made a rapid
and full recovery and was discharged from hospital on day 5 after
administration of investigational product, with resolution of
hypotension, tachycardia, diarrhoea and anuria.
Stool cultures were negative for cryptosporidia, C. difficile, E.coli
0157, Salmonella, Shigella, Campylobacter. No ova, cysts or parasites
were detected on microscopic examination and ELISA for viruses
(adenovirus, norovirus and rotavirus) were negative. There was no
growth from blood or urine cultures and no plasmodium were
visible on blood film on examining for the presence of malaria.
Both polymerase chain reaction (PCR) for rotavirus and norovirus
on stool sample and C.perfringens enterotoxin test on stool were also
negative. There was no rise from baseline to 24 hours post
admission in mast cell tryptase thus reducing the likelihood of
diagnosis of an anaphylactoid-type reaction. Lymphopenia was
reported 4 hours post-dose, but had resolved to within normal
reference range within 2 days.
Immunogenicity
Comparisons between treatment groups for immunogenicity by
ex vivo IFN-c ELISpot showed no overall difference for any of the
parameters tested (Opal-HIV-Gag(c), Mock, Rev, Tat and Nef)
compared to Baseline or placebo. There was an apparent response
in area under the curve (AUC) for Rev (p=0.012 before
correction for multiple tests) for the 12 mg Opal-HIV-Gag(c)
group compared with pooled placebo participants (n=8) (data not
shown; these data are described more fully in a separate
manuscript), but this was not significant after Bonferroni
correction for multiple tests. Individually, there were two
participants, one in each of the 12 mg and 24 mg Opal-HIV-
Gag(c) cohorts, who responded at W14 (2 weeks post-treatment)
compared to Baseline (data not shown; these data are described
more fully in a separate manuscript).
Discussion
This was a first-in-human Phase I, double-blind, placebo-
controlled, dose-escalation study of the safety and immunogenicity
of Opal-HIV-Gag(c) at 3 dose levels in patients with well
controlled HIV-1 infection. The initial clinical trial program
planned for the Opal vaccine was in two initial steps. The current
study was designed as a safety evaluation in patients with well-
controlled viral replication on antiretroviral therapy and without
an interruption to therapy. Subsequent to this study, it was
intended to evaluate efficacy in a Phase I/II study in an adult and
then in a paediatric population where efficacy could be established
in a treatment interruption model.
The study escalated through 12 mg and 24 mg before being
terminated due to a SAE in the 48 mg cohort. Although the
sentinel patient allocated to receive the active product had
tolerated 48 mg without any notable side effects, the second
patient’s hypotension and anuria secondary to diarrhoea and
vomiting occurring approximately 2 hours after dosing led directly
to Sponsor and Investigator-agreed clinical hold. The thorough
investigation included the vaccine, administration method, and the
patient’s recent and past medical history. An identifiable cause for
the event in standard areas of evaluation (infectious agent/food
poisoning, co-morbidities, medical cause other than the study
product, study product not meeting specification and or the study
procedures not being followed) could not be identified. The
incidence of gastrointestinal findings in all other patients between
Opal-HIV-Gag(c) and placebo recipients was similar, and there
was no evidence of immunotoxicity in the GLP toxicology study
conducted in Macaca mulatta.
As a result of the failure to identify an alternative causative
agent or to identify methods of ameliorating the event should it
occur again in other patients, the study was terminated as a safety
precaution.
In all other patients, Opal-HIV-Gag(c) was well tolerated.
Consistent with many phase I studies, headache was the most
commonly reported AE in this study and occurred at similar rates
in patients receiving either Opal-HIV-Gag(c) or placebo. This may
be associated with the study requirements for fasting and caffeine
withdrawal. Consistently observed, was an increased incidence of
fever, rigor, headache and transient, self-limiting lymphopenia in
patients receiving Opal-HIV-Gag(c) at any dose but not placebo
recipients. The temporal association of these events with Opal-
HIV-Gag(c) is consistent with an innate immune response and
provides evidence of a biological response to the peptides rather
than the ex vivo administration method or diluent [16,17].
Adverse events frequently reported in the literature for DMSO
(e.g. sedation, headache, facial flushing [17–19], nausea, vomiting,
abdominal cramps, dizziness [18–20] and a taste of garlic or onion
[20–22] were not observed in this study.
Ex vivo white blood cell enrichment conducted bed-side in the
closed system Biosafe Sepax S-100 device was employed as a more
practical alternative to a laboratory based PBMC separation
methodology. Prior to the conduct of this study, a separate pilot
study was conducted in 6 patients to evaluate the equipment. In
clinical use, the equipment failed on a number of occasions,
limiting its potential for use as a real-time tool for WBC
enrichment.
The translation from animal models to humans remains
problematic in HIV vaccinology with this study non-predictive
for immunogenicity, safety and efficacy between non-human
primates and humans [21,22]. The absence of a clear immuno-
genic signal in this study is in marked contrast to the significant T-
cell immunogenicity observed in studies in Macaca nemestrina with
the Opal vaccination methodology [1,10]. A GLP, repeat dose,
non-human primate (Macaca mulatta) toxicology study was
conducted to evaluate the safety and immunotoxicity of Opal
HIV Gag(c). Eighteen animals were randomly allocated to receive
1.85 or 18.5 milligram (mg) of cGMP Opal HIV Gag(c) in DMSO
or DMSO only (n=6 per group). Treatment was added to whole
blood ex vivo, incubated for 1 hour at 37 degrees (u) Celsius (C),
and reinfused on 5 separate occasions. There were no clinically
relevant adverse findings in either Opal HIV Gag(c) or control
animals with all animals remaining healthy throughout the study.
There were no treatment related changes in haematology, serum
chemistries or urinalysis, and no relevant histological findings
upon necropsy.
The exposure to peptides, and the number of cells exposed to
peptides ex vivo were both within the range or greater than that
used in the Macaca nemestrina studies (0.035 to 0.07 mg peptides per
million WBC in non-human primates compared to 0.018 to
0.285 mg peptides per million WBC in this study). In determining
the adequacy of the clinical dose for immunogenicity purposes,
both the amount of Opal HIV Gag(c) and the number of PBMCs
exposed have been taken into account. Allometric scaling on body
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required in the clinic to yield a proportionally similar number of
PBMCs to that shown to be effective in macaques. The blood
volume ranged from 29.5 mL to 120 mL, and thus 120 mL of
venous blood was drawn from each patient. From the non-human
primate non-clinical studies, it was estimated that 96106 to
1.86107 PBMCs were exposed to peptides at each administration
for each macaque. Allometrically scaling this to humans (based on
BSA) yielded an ideal PBMC count of 5.96107 to 1.26108 for
Opal treatment per person, the range achieved in the clinical trial.
Finally, a range of 0.035 mg to 0.07 mg of peptide per million
PBMCs was shown to be efficacious in the non-human primate
model. Extrapolating this to humans with the expected PBMC
yield from 120 mL of whole blood requires a range of minimum
doses of 4.2 to 16.8 mg per administration. The clinical doses
evaluated span this range with the minimum dose of 12 mg and
the maximum dose of 48 mg.
In conclusion, in this double blind, placebo controlled, dose
escalation study, Opal-HIV-Gag(c)) was generally well tolerated in
adults with well-controlled HIV-1 infection at doses of 12 and
24 mg. There was an increased incidence of pyrexia, chills, rigor,
and transient (and self-limiting) lymphopaenia in Opal-HIV-
Gag(c) recipients compared to placebo. There were no clear
differences in dose on the incidence of laboratory abnormalities or
the nature, incidence or severity of adverse events. There was no
evidence of a treatment effect on T-cell responses, measured by ex
vivo ELISpot, after administration of Opal-HIV-Gag(c).). An SAE
of life-threatening hypotension at a dose of 48 mg lead to early,
precautionary termination of the study. Further development of
OPAL will not be undertaken in the current form.
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